Thursday Morning Headlines

Yesterday was dominated by Biogen's news on their Alzheimer drug, but there was other news including Sarepta getting slapped with a clincial hold, Gilead CEO stepping down and, although not Life Science related, Facebook getting crushed after their earnings.  Here is what I'm reading: Yesterday afternoon Eisai & Biogen Revealed Promising Alzheimer’s Data But Questions … Continue reading Thursday Morning Headlines

Tuesday Morning Headlines

Good morning, this is what I'm reading on this hot and humid Tuesday morning: For Scientists Racing to Cure Alzheimer’s, the Patient Recruitment Math Is Getting Ugly (NY Times) Anthem In Telehealth Deal With Samsung And American Well (Forbes) An Enormous Study of the Genes Related to Staying in School. Researchers have found 1,271 gene … Continue reading Tuesday Morning Headlines

Monday Morning Reads

Here is what I'm reading as we kick off the workweek: This Startup Is Developing Finger-Prick Blood Tests, But Don't Call It Theranos 2 (Forbes) The Week Ahead In Biotech: Conferences, Clinical Trial Results, IPOs and More (Benzinga). Azar says 'change is coming' for 340B (BioPharma Dive) This smartwatch with an Uber-like twist is aiming … Continue reading Monday Morning Reads

Monday Morning Reads

Good morning, hopefully you had a great weekend and perhaps were lucky enough to have an extended weekend.  Here is what I am reading as we start the work week: Biogen and Eisai released data from their Alzheimer clinical trial last week and the market responded very positively, but are the results really what they … Continue reading Monday Morning Reads

Thursday Morning Reads

Good morning, all.  This is what I am reading this morning: Finding patients can always be a difficult task when conducting a clinical trial, but even more so when a doctor has to conduct an expensive genetic test that detects 1% of the population – “Finding Cancer Patients Is the Pharma Industry’s Unlikely Challenge” Buffett, … Continue reading Thursday Morning Reads